Bloom Burton upgraded shares of Repare Therapeutics (NASDAQ:RPTX – Free Report) from an accumulate rating to a buy rating in a research note issued to investors on Friday, Zacks.com reports.
Separately, HC Wainwright reiterated a buy rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Wednesday, February 21st.
Check Out Our Latest Stock Analysis on Repare Therapeutics
Repare Therapeutics Price Performance
Repare Therapeutics (NASDAQ:RPTX – Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.11). The business had revenue of $13.05 million during the quarter, compared to analyst estimates of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative return on equity of 39.82%. Equities research analysts expect that Repare Therapeutics will post -2.74 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Repare Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank boosted its position in Repare Therapeutics by 7.0% during the first quarter. Swiss National Bank now owns 39,500 shares of the company’s stock worth $562,000 after purchasing an additional 2,600 shares during the period. JPMorgan Chase & Co. boosted its position in Repare Therapeutics by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after purchasing an additional 1,253 shares during the period. BlackRock Inc. boosted its position in Repare Therapeutics by 1.9% during the first quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock worth $6,655,000 after purchasing an additional 8,680 shares during the period. Affinity Asset Advisors LLC boosted its position in Repare Therapeutics by 72.5% during the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock worth $6,677,000 after purchasing an additional 197,127 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Repare Therapeutics by 1.6% during the first quarter. Renaissance Technologies LLC now owns 88,100 shares of the company’s stock worth $1,255,000 after purchasing an additional 1,400 shares during the period. Institutional investors and hedge funds own 85.09% of the company’s stock.
About Repare Therapeutics
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Read More
- Five stocks we like better than Repare Therapeutics
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 4/15 – 4/19
- Technology Stocks Explained: Here’s What to Know About Tech
- Comprehensive Analysis of PayPal Stock
- Health Care Stocks Explained: Why You Might Want to Invest
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.